SPOTLIGHT -
A review of agents in late-stage development for the treatment of HIV/AIDS (April 2005).
FDA Clears Narcan OTC for Opioid Overdoses
Emergent BioSolutions hasn’t provided a price for the nonprescription Narcan but said the product will be available by late summer.
FDA Schedules Advisory Committee Meeting for OTC Contraceptive
If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.
Ohio Sues Express Scripts and Prime Therapeutics For Price Fixing
The suit alleges that Express Scripts, Prime and Prime customer Humana Pharmacy Solutions are able to share drug pricing and rebate information to increase prices for insulins, biologics and cancer drugs.
Generics Keep Out-of-Pocket Costs Low for Women with Breast Cancer
Out-of-pockets costs were higher among those using branded or more recently launched drugs.
RxBenefits Provides New Solutions to Facilitate Access to Patient Assistance Programs
RxBenefits helps patients in self-funded plans find and apply for alternative sources of funding for specialty medicines and facilitates enrollment.
FDA Approves First Treatment for Rare Immunodeficiency Disease
Leniolisib, now with the brand name Joenja, treats APDA, a genetic disorder that impairs the immune system. It will have an annual list price of $547,500 a year.